Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77285.950.1011%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Bio-Rad Laboratories Inc

BIONYSE
Trade with Public
Trade with Public
$369.32
0.570.15%
At close: Sep 11, 5:00 PM EST
$369.32
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Bio-Rad Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bio-Rad Laboratories (BIO).

Price Target Range — 12 Quarters

Analyst Consensus — 4 Analysts

2Buy
2Hold
Consensus RatingEqual-Weight# Analysts4Avg. Consensus PT$334Upside to Avg. PT-9.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026RBC CapitalDan LeonardPT RaiseOutperform$370→$390
Aug 5, 2026CitigroupDaniel GrosslightPT RaiseNeutral$300→$330
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
Benzinga Newsdesk

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved